Singapore – April 5, 2024 – Us2.ai, a leading MedTech firm backed by prominent investors including IHH Healthcare, Heal Partners, Peak XV Partners (formerly Sequoia India) and EDBI, announces FDA...
Envisia is a biotechnology company that licensed technology from Liquidia Technologies and is focused on the development of novel ocular therapies by leveraging the unique and powerful properties of the PRINT® platform. The company’s lead program, ENV515, is a novel extended-release formulation of a prostaglandin analogue for the treatment of glaucoma. It has the potential to offer glaucoma patients an innovative product that can provide sustained reduction in IOP over many months after a single administration.
Envisia Therapeutics
Research Triangle Park, NC
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.